文献速递前列腺增生与排尿功能障碍泌尿系感染

膀胱过度活动症药物治疗对尿路感染发生率及相关因素的影响:系统综述与Meta分析

Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis.
PubMed 文献 · J Urol · 2023-02-14

该系统综述与Meta分析检索MEDLINE和Cochrane图书馆,纳入33项试验共35939例膀胱过度活动症患者,比较抗毒蕈碱药或β3肾上腺素受体激动剂与安慰剂。治疗1-3个月后,抗毒蕈碱药组尿路感染发生率显著高于安慰剂组(RR 1.23,95%CI 1.04-1.45,P=.013),β3肾上腺素受体激动剂组未升高(RR 1.04,95%CI 0.76-1.42,P=.796)。

要点

  • 抗毒蕈碱药治疗1-3个月尿路感染风险高于安慰剂(RR 1.23,95%CI 1.04-1.45,P=.013)。
  • β3肾上腺素受体激动剂未增加尿路感染风险(RR 1.04,95%CI 0.76-1.42,P=.796)。
  • 抗毒蕈碱药增加尿潴留、排尿困难或残余尿量增加风险(RR 2.88,95%CI 1.79-4.63,P<.001)。

核心结论

  • 抗毒蕈碱药显著增加尿路感染及下尿路症状与功能障碍发生率,β3肾上腺素受体激动剂未增加。
  • 作者认为,为预防尿路感染发生,β3肾上腺素受体激动剂可能比抗毒蕈碱药更安全。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE和Cochrane图书馆。
  • 共纳入33项试验、35939例膀胱过度活动症患者,其中29项为抗毒蕈碱药对比安慰剂、9项为β3肾上腺素受体激动剂对比安慰剂。
  • 采用随机效应模型进行Meta分析。

主要发现

  • 治疗1-3个月后,抗毒蕈碱药组尿路感染发生率显著高于安慰剂组(RR 1.23,95%CI 1.04-1.45,P=.013)。
  • β3肾上腺素受体激动剂组尿路感染发生率未升高(RR 1.04,95%CI 0.76-1.42,P=.796)。
  • 抗毒蕈碱药显著增加尿潴留、排尿困难和/或残余尿量增加风险(RR 2.88,95%CI 1.79-4.63,P<.001)。
  • β3肾上腺素受体激动剂未显著增加尿潴留、排尿困难和/或残余尿量增加风险(RR 1.26,95%CI 0.38-4.14,P=.708)。

临床怎么用

  • 作者认为,为预防尿路感染发生,β3肾上腺素受体激动剂可能比抗毒蕈碱药更安全。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this meta-analysis was to investigate the effect of pharmacotherapy for overactive bladder on the pathogenesis of urinary tract infection. MATERIALS AND METHODS: A comprehensive search was performed in MEDLINE and the Cochrane Library using terms for overactive bladder, antimuscarinic agents, and beta 3-adrenoceptor agonists. The primary end point was the emergence of urinary tract infection after pharmacotherapy for overactive bladder. The secondary end point was the emergence of urinary retention, dysuria, and/or increased residual urine volume after overactive bladder treatment. Meta-analyses were conducted using random-effects models. RESULTS: A total of 35,939 patients in 33 trials (29 trials of antimuscarinic agents vs placebo, and 9 trials of beta 3-adrenoceptor agonists vs placebo) that included patients with overactive bladder were identified. At 1-3 months after treatment, the incidence of urinary tract infections was statistically significantly higher in the patients treated with antimuscarinic agents (RR: 1.23, 95% CI: 1.04, 1.45; P = .013) than in the placebo control group. The incidence of urinary tract infections was not increased in the patients treated with beta 3-adrenoceptor agonists (RR: 1.04, 95% CI: 0.76, 1.42; P = .796). Antimuscarinic agents also statistically significantly increased the risks of urinary retention, dysuria, and/or increased residual urine volume (RR: 2.88, 95% CI: 1.79, 4.63; P < .001), whereas beta 3-adrenoceptor agonists did not (RR: 1.26, 95% CI: 0.38, 4.14; P = .708). CONCLUSIONS: This meta-analysis showed that antimuscarinic agents statistically significantly increased the incidences of urinary tract infection and lower urinary tract symptoms and dysfunction, but beta 3-adrenoceptor agonists did not. To prevent urinary tract infection emergence, beta 3-adrenoceptor agonists might be safer than antimuscarinic agents.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Tsubouchi K, Arima H, Abe M, et al. Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis. J Urol. 2023. PMID: 36787147. doi:10.1097/JU.0000000000003209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。